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ABSTRACT 
Pulmonary artery hypertension is a common cardiovascular complication in preterm infants with bronchopulmo-
nary dysplasia which is associated with increased morbidity and mortality. Inhaled iloprost is used as a therapeutic 
option in pulmonary hypertension, especially in adults. There have been but a few reports on the use of iloprost for 
neonates and infants. We report the case of a 5 month-old-male infant who received neonatal intensive care for 
4 months due to respiratory distress syndrome and prematurity, during which he developed bronchopulmonary 
dysplasia. Echocardiography showed severe pulmonary hypertension. The initial treatment included respiratory 
support with high frequency oscillatory ventilation (HFOV); however, his clinical condition did not improve. In-
haled iloprost with sildenafil, an oral phosphodiesterase-5 inhibitor, was thus used. With the administration of 
iloprost and sildenafil, his condition improved and he was weaned from oxygen. Our clinical experience suggests 
that iloprost is a promising therapy for pulmonary hypertension, especially when inhaled nitric oxide is unavailable. 
(Korean Circ J 2009;39:343-345) 
 
KEY WORDS: Pulmonary hypertension; Bronchopulmonary dysplasia; Iloprost. 
 
 
Introduction 
 
Inhaled iloprost is used as a therapeutic option for pul-
monary hypertension, especially in adults; however, have 
been but a few reports on the use of iloprost in neonates 
and infants. Prostacyclin (PGI2) is an arachidonic acid 
metabolite formed by prostacyclin synthase in the vas-
cular endothelium. Its effect on vascular tone is medi-
ated by an increment in adenosine 3’:5’-cyclic mono-
phosphate (cAMP) levels and is comparable to that of 
inhaled nitric oxide (NO), which increases the cyclic gua-
nosine monophosphate (cGMP) levels. Herein we report 
the use of iloprost in treating pulmonary hypertension 
in an infant with bronchopulmonary dysplasia (BPD). 
Inhaled iloprost reduced the pulmonary hypertension 
and improved oxygenation without decreasing the sys-
temic blood pressure.   
 
Case 
 
A 5-month-old male infant was brought to the pre-
mature baby clinic with severe dyspnea and chest re-
tractions. He was immediately transferred to the intensive 
care unit. 
The infant was born at 26 weeks of gestation via cae-
sarean section because of acute chorioamninitis and pla-
centitis. The birth weight was 800 gm. He received neo-
natal intensive care due to respiratory distress syndrome 
and prematurity, during which he developed BPD. He 
was discharged from the neonatal intensive care unit in 
stable condition after 4 months. The initial oxygen satu-
ration was 80%. The liver was palpated 4 cm below the 
right subcostal margin. A chest radiograph showed se-
vere cardiomegaly and BPD (Fig. 1). Based on echocar-
diography, the pulmonary pressure was elevated, with a 
pressure gradient (TR PG) of 48 mmHg and there was 
a severely dilated right ventricle (RV) with tricuspid valve 
regurgitation (Fig. 2). 
Therapeutic strategies were aimed at optimizing res-
piratory function and alkalinization in order to decrease 
the pulmonary artery pressure. The initial treatments in-
cluded respiratory support with high frequency oscil-
latory ventilation (HFOV) and sildenafil (3 mg/kg/day), 
an oral phosphodiesterase-5 inhibitor; however, the clin-
ical condition had not improved significantly by the 3rd 
hospital day. The infant had chest retractions and the 
oxygen saturation was between 70% and 80%. His oxy-
gen requirements progressively increased, persistent car-
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diomegaly was noted on the chest radiograph, and serial 
echocardiograms showed pulmonary hypertension, thus 
the HFOV was discontinued. 
NO was not available at our hospital, therefore inhaled 
iloprost was added with continuous oral sildenafil. We 
applied iloprost through an aerosolizing circuit and ne-
bulizer for 20 days. With the additional administration 
of iloprost, his condition improved and he was weaned 
from oxygen. A follow-up chest radiograph showed im-
provement in the cardiomegaly (Fig. 3). The inhaled ilo-
prost increased the oxygenation (saturation >95%). Serial 
echocardiograms showed mild elevated pulmonary pres-
sure, with a TR PG of 34 mmHg and a decrease in the 
size of the RV (Fig. 4).  
Enteral nutrition was successful. The hepatomegaly 
was resolving. After 23 days, he was discharged with a 
normal oxygen saturation on room air. 
Discussion 
 
Pulmonary artery hypertension (PAH) is a common 
cardiovascular complication in preterm infants with BPD 
and is associated with increased morbidity and mortal-
ity.
1)2) 
PAH is characterized by elevation of the pulmonary 
artery pressure and pulmonary vascular resistance, which 
can lead to progressive right heart failure and death.
3-6) 
Premature infants with BPD and severe PAH are at a 
high risk of death, particularly during the first 6 months 
after the diagnosis of PAH.
7) 
On the basis of advances in vascular biology and kn-
own pathogenic mechanisms underlying PAH, three gen-
eral classes of therapeutic agents have been developed 
and are currently available for the treatment of PAH, 
including prostacyclin analogues (epoprostenol, trepro-
Fig. 1. Initial chest radiography showed severe cardiomegaly. Fig. 3. Chest radiography showed improvement in cardiomegaly
on follow-up after 2 months later. 
Fig. 2. Based on echocardiography, the pulmonary pressure was elevated, with a pressure gradient (TR PG) of 48 mmHg (A) and there 
was a severely dilated right ventricle (RV) with tricuspid valve regurgitation (B). 
A  B  
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stinil, and iloprost), endothelin receptor antagonists (bo-
sentan and ambrisentan), and phosphodiesterase inhib-
itors (sildenafil).
5)8)9) 
Iloprost is a prostacyclin-analog which is an impor-
tant mediator of pulmonary vasodilatation. However, 
few data are available about its use in the critical care of 
infants. Ivy et al.
10) reported the safety and efficacy of in-
haled iloprost in pediatric patients with PAH; the acute 
pulmonary vasodilator response to inhaled iloprost was 
equivalent to the effects of inhaled NO.
10) 
Our clinical experience indicates that iloprost is a 
promising therapy for pulmonary hypertension, espe-
cially in situations in which inhaled NO is unavailable. 
Direct lung administration is the main advantage of ilo-
prost. Future studies are warranted to better define the 
safety and efficacy of iloprost in comparison with other 
vasodilator drugs. 
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Fig. 4. The inhaled iloprost increased the oxygenation (saturation >95%). Serial echocardiograms showed mild elevated pulmonary pres-
sure, with a TR PG of 34 mmHg (A) and a decrease in the size of the RV (B). RV: right ventricle. 
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